The FDA has approved, for the first time, a transcathter heart valve for valve-in-valve (VIV) procedures in patients whose surgical aortic heart valves have failed. The agency expanded the approved use of Medtronic's (Dublin, Ireland) CoreValve system for VIV procedures in patients in need of a second valve replacement who are at high or extreme risk for complications associated with traditional open-heart surgery. Read More
